Congressional Research Service Reports - 388 Matching Results

Search Results

Results: 1 - 24 next
open access

Medicare: Beneficiary Cost-Sharing Under Prescription Drug Legislation

Description: This report provides an analysis of how the cost-sharing and premium provisions under the Prescription Drug and Medicare Improvement Act of 2003 (S. 1) and the Medicare Prescription Drug and Modernization Act of 2003 (H bill would affect the amount that a beneficiary would pay annually for prescription drugs.
Date: July 25, 2003
Creator: Peterson, Chris L.
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
open access

Medicare: Beneficiary Cost-Sharing Under Proposed Prescription Drug Benefits

Description: This report examines these proposals as well as the “Medicare Rx Drug Benefit and Discount Act of 2003,” which was introduced by Representative Charles Rangel, the ranking member of the House Ways and Means Committee. Specifically, this report provides background on how the cost-sharing and premium provisions under each bill would affect the amount that a beneficiary pays annually for prescription drugs.
Date: June 17, 2003
Creator: Peterson, Chris L.
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
open access

Medicare: Beneficiary Cost-Sharing Under Proposed Prescription Drug Benefits

Description: This report provides background on how the cost-sharing and premium provisions under each bill would affect the amount that a beneficiary pays annually for prescription drugs. In addition, this report gives examples of how annual cost-sharing would differ for beneficiaries with various levels of total prescription drug spending in 2006 under the plans.
Date: June 26, 2003
Creator: Peterson, Chris L.
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
open access

Medicare Prescription Drug and Reform Legislation

Description: This report describes the major features of S. 1, as ordered reported, and the measure to be considered by the House Ways and Means Committee, H.R. 2473, as ordered reported.
Date: June 19, 2003
Creator: O'Sullivan, Jennifer; Chaikind, Hinda Ripps; Tilson, Sibyl L.; Boulanger, Jennifer & Morgan, Paulette C.
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
open access

Federal R&D, Drug Discovery, and Pricing: Insights from the NIH-University-Industry Relationship

Description: Interest in methods to provide drugs at lower cost, particularly for the elderly, has rekindled discussion over the role the federal government plays in facilitating the creation of new pharmaceuticals for the marketplace. This report explores the issue of whether or not the substantial federal investment in health-related research and development (R&D) entitles the public to commensurate consideration in prices charged for any resulting drugs. It is intended to provide the reader with an under… more
Date: June 19, 2000
Creator: Schacht, Wendy H.
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: September 10, 2001
Creator: Redhead, C. Stephen
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: October 3, 2002
Creator: Redhead, C. Stephen
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: January 3, 2003
Creator: Redhead, C. Stephen
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: June 11, 2003
Creator: Redhead, C. Stephen
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: March 10, 2004
Creator: Redhead, C. Stephen
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
Date: November 25, 2002
Creator: Schacht, Wendy H. & Thomas, John R.
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
Date: January 16, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on the Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: May 8, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: June 23, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: June 30, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Item Type: Refine your search to only Report
Partner: UNT Libraries Government Documents Department
Back to Top of Screen